2 1 Shi Ji Jing Ji Bao Dao·2025-09-30 04:49Group 1 - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (Baiyunshan) and Nanjing Pharmaceutical Co., Ltd. announced a strategic investment agreement, where Baiyunshan's Guangzhou Guangyao Phase II Fund will invest approximately 748.81 million RMB to acquire 11.04% of Nanjing Pharmaceutical's shares [1][2] - The acquisition price is set at 5.18 RMB per share, based on the average closing price over the previous 60 trading days [1] - This acquisition marks the first major strategic investment project since the new leadership team at Baiyunshan took office, signaling a strong commitment to capital operations and innovation in collaboration with leading regional enterprises [3] Group 2 - The strategic cooperation agreement includes capital collaboration, distribution channel cooperation, and collaboration in traditional Chinese medicine [2] - In terms of capital cooperation, the parties will explore joint ventures, strategic investments, and equity investment funds as needed [2] - The collaboration aims to enhance supply chain efficiency and establish a comprehensive traceability system for traditional Chinese medicine from cultivation to sales [2][3] Group 3 - The Guangyao Phase II Fund, established with an investment of 1.4985 billion RMB from Baiyunshan, focuses on investments in the biopharmaceutical and health sectors [3] - The partnership between Baiyunshan and Nanjing Pharmaceutical is expected to drive regional network complementarity and supply chain technology collaboration, contributing to the ongoing consolidation trend in the pharmaceutical distribution industry [3]